MRI-guided, open trial of abciximab for ischemic stroke within a 3- to 24-hour window.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 16116128.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors assessed the effect of IV abciximab on early neurologic improvement and ischemic lesion growth in 29 patients with supratentorial stroke and NIH stroke scale score (NIHSSS) > or = 4 (11.1 +/- 5.9), treated within 3 to 24 (13.6 +/- 5.5) hours of onset. The 48 to 72-hour NIHSSS improvement was 4.4 +/- 3.2 and the 24-hour lesion growth on DWI was +23% (-50%, +103%); 7/26 (27%) patients experienced lesion size decrease. Treatment of sub-24-hour stroke with abciximab improves early post-treatment neurologic status and often attenuates ischemic lesion growth.
Medical subject headings
- Antibodies, Monoclonal
- Anticoagulants
- Brain
- Brain Ischemia
- Immunoglobulin Fab Fragments
- Stroke